AMGN - Amgen Is A Fantastic Dividend Growth Stock With A Weight-Loss Wild Card

2024-06-04 07:30:00 ET

Summary

• The obesity market is expected to reach $130 billion by 2030, benefiting companies like Eli Lilly and Novo Nordisk.
• Amgen, a biotech company, is experiencing innovation-fueled growth with impressive new products and international expansion.
• Amgen offers shareholder value with a strong financial performance, dividend hikes, and a favorable valuation.

Introduction

I imagine the dream of every Formula 1 driver is to win a Championship, the dream of every football player is to win the Super Bowl, and the dream of every politician to eventually call the Oval Office their workplace.

Healthcare/biotech investors probably dream of their companies launching a product that is as successful as the latest weight loss drugs from Eli Lilly ( LLY ) and Novo Nordisk ( NVO ), whose shares have gained 611% and 471% over the past five years alone, respectively....

For further details see: